Split History
ETFs Holding CASC »    CASC Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. Co.'s primary development candidate, tucatinib, is an orally bioavailable, potent tyrosine kinase inhibitor that is selective for HER2, a growth factor receptor that is over-expressed in about 20.0% of breast cancers. Co. is developing tucatinib for the treatment of HER2-positive metastatic breast cancer. Co.'s earlier stage product candidate, CASC-578, is a checkpoint kinase 1 cell cycle inhibitor that is an orally available, small molecule kinase inhibitor and additionally Co. has an antibody against an immuno-oncology target known as TIGIT. According to our CASC split history records, Cascadian Therapeutics has had 1 split.
CASC split history picture
Cascadian Therapeutics (CASC) has 1 split in our CASC split history database. The split for CASC took place on November 29, 2016. This was a 1 for 6 reverse split, meaning for each 6 shares of CASC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.

When a company such as Cascadian Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share. Looking at the CASC split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cascadian Therapeutics shares, starting with a $10,000 purchase of CASC, presented on a split-history-adjusted basis factoring in the complete CASC split history. CASC split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 11/19/2007
End date: 11/17/2017
Start price/share: $3.06
End price/share: $4.01
Dividends collected/share: $0.00
Total return: 31.05%
Average Annual Total Return: 2.74%
Starting investment: $10,000.00
Ending investment: $13,104.72
Years: 10.00
Date Ratio
11/29/20161 for 6
CASC is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CBIO Split History
CBLI Split History
CBM Split History
CBMX Split History
CBRX Split History
CCM Split History
CDXC Split History
CELG Split History
CERE Split History
CERU Split History

Amedica Corporation (AMDA)
Patrick Industries, Inc. (PATK)
Whiting Petroleum Corporation (WLL)
SPI Energy Co., Ltd. (SPI)
CytRx Corporation (CYTR)
Marathon Patent Group, Inc. (MARA)
WisdomTree U.S. Total Earnings Fund (EXT)
WisdomTree U.S. Earnings 500 Fund (EPS)
WisdomTree U.S. SmallCap Dividend Fund (DES)
WisdomTree U.S. MidCap Dividend Fund (DON)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CASC Insider Buying

CASC Split History | www.SplitHistory.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.